Jazz Pharma Upgraded to Strong Buy - Analyst Blog

A generic image of a person on their smartphone
Credit: Shutterstock photo

On Nov 8, 2013, Zacks Investment Research upgraded Jazz Pharmaceuticals ( JAZZ ) to a Zacks Rank #1 (Strong Buy).

Why the Upgrade?

Jazz Pharma has been witnessing rising earnings estimates on the back of strong third quarter 2013 results. Moreover, this specialty biopharmaceutical company delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 3.93%. The long-term expected earnings growth rate for this stock is 25.3%

Jazz Pharma reported third quarter 2013 results on Nov 5. Adjusted earnings of $1.66 per share were well above the Zacks Consensus Estimate of $1.52 and the year-ago adjusted earnings of $1.22 per share. Including stock-based compensation expense and depreciation, earnings were $1.61 per share. Investors reacted positively to the news. Overall, the stock gained 6.1% since the announcement.

Earnings were primarily aided by solid top-line growth of 32.3% driven by strong sales of Xyrem (narcolepsy) and Erwinaze (oncology).

Based on its progress, the company raised the low end of its earnings per share projection to $6.30 to $6.40 per share (previous guidance: $6.20 to $6.40). Jazz Pharma tweaked its revenue guidance to $867-$877 million from $860-$880 million expected earlier.

The Zacks Consensus Estimate for 2013 increased 10 cents to $5.77 per share as several firms raised their estimates over the last 7 days. For 2014, estimates were revised higher over the same time frame, lifting the Zacks Consensus Estimate by 43 cents to $7.78 per share.

Other Stocks to Consider

Other companies in the pharma space with a favorable Zacks Rank are AMAG Pharmaceuticals, Inc. ( AMAG ), Pharmacyclics Inc. ( PCYC ) and Osiris Therapeutics, Inc. ( OSIR ). All these stocks also carry a Zacks Rank #1.

AMAG PHARMA INC (AMAG): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

PHARMACYCLICS (PCYC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More